Suppr超能文献

利妥昔单抗治疗自身免疫性疾病和肾小球疾病后持续性B细胞耗竭:病例系列

Persistent B Cell Depletion After Rituximab for Autoimmune and Glomerular Diseases: A Case Series.

作者信息

Efe Orhan, Sauvage Gabriel, Jeyabalan Anushya, Al Jurdi Ayman, Seethapathy Harish S, Cosgrove Katherine, Cortazar Frank B, Laliberte Karen A, Zonozi Reza, Niles John L

机构信息

Vasculitis and Glomerulonephritis Center, Massachusetts General Hospital, Boston, Massachusetts, USA.

Division of Nephrology, Massachusetts General Hospital, Boston, Massachusetts, USA.

出版信息

Kidney Int Rep. 2025 Feb 7;10(5):1441-1449. doi: 10.1016/j.ekir.2025.02.002. eCollection 2025 May.

Abstract

INTRODUCTION

Persistent B cell depletion is a rare complication of rituximab treatment, and its clinical implications are unknown.

METHODS

This retrospective case series included patients with glomerular and autoimmune diseases who developed persistent B cell depletion (< 5 CD19CD20 cells/μl persisting for > 2 years) after the last rituximab dose.

RESULTS

Among 1519 patients who received rituximab, 2% ( = 30) had persistent B cell depletion. The frequencies of persistent B cell depletion were 2.5% (22 of 878), 2.4% (2 of 82), and 0.8% (1 of 114) in antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV), systemic lupus erythematosus (SLE) or lupus nephritis, and podocytopathies, respectively. The remaining patients had ANCA-negative vasculitis ( = 2), anti-glomerular basement membrane disease ( = 1), Behcet's disease ( = 1), and polymyositis ( = 1). The median age was 64.5 (interquartile range [IQR]: 44-77) years. Before the last dose of rituximab, all patients except 2 used cytotoxic agents, often prolonged (> 1 year) or recycling courses, and 60% (18 of 30) received a period of long-term maintenance steroids. By 4 years after the last rituximab dose, only 30% had B cell repopulation. In those who experienced B cell repopulation, B cell counts remained very low, at a median of 7(6-15) cells/μl at the last follow-up. After the last rituximab dose, 83% (23 of 30) had sustained disease remission. Late-onset neutropenia, recurrent infections, and severe infections occurred in 23% (7 of 30), 47% (14 of 30), and 57% (17 of 57), respectively. Of the patients, 23% (7 of 30) required immunoglobulin replacement, and 30% (9 of 30) died, mostly from complications of chronic diseases.

CONCLUSION

Persistent B cell depletion is a rare complication of rituximab treatment, mostly affecting patients with exposure(s) to cytotoxic therapies for recurrent diseases. It is characterized by prolonged disease remission and increased infection risk.

摘要

引言

持续性B细胞耗竭是利妥昔单抗治疗罕见的并发症,其临床意义尚不清楚。

方法

本回顾性病例系列纳入了肾小球疾病和自身免疫性疾病患者,这些患者在最后一剂利妥昔单抗后出现持续性B细胞耗竭(<5个CD19⁺CD20⁺细胞/μl,持续超过2年)。

结果

在1519例接受利妥昔单抗治疗的患者中,2%(n = 30)出现持续性B细胞耗竭。抗中性粒细胞胞浆抗体(ANCA)相关性血管炎(AAV)、系统性红斑狼疮(SLE)或狼疮性肾炎以及足细胞病患者中持续性B细胞耗竭的发生率分别为2.5%(878例中的22例)、2.4%(82例中的2例)和0.8%(114例中的1例)。其余患者患有ANCA阴性血管炎(n = 2)、抗肾小球基底膜病(n = 1)、白塞病(n = 1)和多发性肌炎(n = 1)。中位年龄为64.5岁(四分位间距[IQR]:44 - 77岁)。在最后一剂利妥昔单抗之前,除2例患者外,所有患者均使用了细胞毒性药物,通常疗程延长(>1年)或循环使用,60%(30例中的18例)接受了一段长期维持性类固醇治疗。在最后一剂利妥昔单抗后4年时,只有30%的患者B细胞重新增殖。在那些经历B细胞重新增殖的患者中,B细胞计数仍然非常低,最后一次随访时中位计数为7(6 - 15)个细胞/μl。在最后一剂利妥昔单抗后,83%(30例中的23例)疾病持续缓解。迟发性中性粒细胞减少、反复感染和严重感染的发生率分别为23%(30例中的7例)、47%(30例中的14例)和57%(57例中的17例)。23%(7例中的30例)的患者需要免疫球蛋白替代治疗,30%(9例中的30例)死亡,多数死于慢性疾病并发症。

结论

持续性B细胞耗竭是利妥昔单抗治疗罕见的并发症,主要影响因复发性疾病而接受细胞毒性治疗的患者。其特点是疾病缓解期延长和感染风险增加。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e76/12142800/1fa042ffe354/ga1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验